A review of phage therapy against bacterial pathogens of aquatic and terrestrial organisms

Viruses

Volumn 9, Issue 3, 2017, Pages

  Doss, Janis ^a   Culbertson, Kayla ^a   Hahn, Delilah ^a   Camacho, Joanna ^a   Barekzi, Nazir ^a  

^a OLD DOMINION UNIVERSITY   (United States)

Author keywords

Aquaculture; Bacteriophage; Phage therapy; Vibrio phage

Indexed keywords

ANTIINFECTIVE AGENT; BACTERIOPHAGE DNA; ENDOLYSIN; ENDOTOXIN; HOLIN; LINEZOLID; MEMBRANE PROTEIN; PEPTIDOGLYCAN; PHYTOHEMAGGLUTININ; UNCLASSIFIED DRUG; VIRION ASSOCIATED PEPTIDOGLYCAN HYDROLASE; VIRULENCE FACTOR;

ANTIBIOTIC RESISTANCE; BACTERIAL GENOME; BACTERIOPHAGE; CONCENTRATION (PARAMETERS); FOOD PROCESSING; HORIZONTAL GENE TRANSFER; HUMAN; LIFE CYCLE; MARINE BACTERIUM; NONHUMAN; PHAGE THERAPY; REVIEW; ANIMAL; BACTERIAL INFECTIONS; PLANT;

ANIMALS; BACTERIAL INFECTIONS; HUMANS; PHAGE THERAPY; PLANTS;

EID: 85015843460     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v9030050     Document Type: Review

References (40)

1. Henry, M.; Debarbieux, L. Tools from viruses: Bacteriophage successes and beyond. Virology 2012, 434, 151–161. [CrossRef] [PubMed]
2. Golkar, Z.; Bagasra, O.; Pace, D.G. Bacteriophage therapy: A potential solution for the antibiotic resistance crisis. J. Infect. Dev. Ctries. 2014, 8, 129–136. [CrossRef] [PubMed]
3. Salmond, G.P.; Fineran, P.C. A century of the phage: Past, present and future. Nat. Rev. Microbiol. 2015, 13, 777–786. [CrossRef] [PubMed]
4. Haq, I.U.; Chaudhry, W.N.; Akhtar, M.N.; Andleeb, S.; Qadri, I. Bacteriophages and their implications on future biotechnology: A review. Virol. J. 2012, 9, 9. [CrossRef] [PubMed]
5. Wittebole, X.; De Roock, S.; Opal, S.M. A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 2014, 5, 226–235. [CrossRef] [PubMed]
6. Sulakvelidze, A.; Alavidze, Z.; Morris, J.G., Jr. Bacteriophage therapy. Antimicrob. Agents Chemother. 2001, 45, 649–659. [CrossRef] [PubMed]
7. Forterre, P. To be or not to be alive: How recent discoveries challenge the traditional definitions of viruses and life. Stud. Hist. Philos. Sci. C 2016, 59, 100–108. [CrossRef] [PubMed]
8. Erez, Z.; Steinberger-Levy, I.; Shamir, M.; Doron, S.; Stokar-Avihail, A.; Peleg, Y.; Melamed, S.; Leavitt, A.; Savidor, A.; Albeck, S.; et al. Communication between viruses guides lysis–lysogeny decisions. Nature 2017, 541, 488–493. [CrossRef] [PubMed]
9. Chaikeeratisak, V.; Nguyen, K.; Khanna, K.; Brilot, A.F.; Erb, M.L.; Coker, J.K.; Vavilina, A.; Newton, G.L.; Buschauer, R.; Pogliano, K. Assembly of a nucleus-like structure during viral replication in bacteria. Science 2017, 355, 194–197. [CrossRef] [PubMed]
10. Penadés, J.R.; Chen, J.; Quiles-Puchalt, N.; Carpena, N.; Novick, R.P. Bacteriophage-mediated spread of bacterial virulence genes. Curr. Opin. Microbiol. 2015, 23, 171–178. [CrossRef] [PubMed]
11. Seed, K.D. Battling Phages: How Bacteria Defend against Viral Attack. PLoS Pathogens 2015, 11, e1004847. [CrossRef] [PubMed]
12. Barrangou, R. The roles of CRISPR–Cas systems in adaptive immunity and beyond. Curr. Opin. Immunol. 2015, 32, 36–41. [CrossRef] [PubMed]
13. Seed, K.D.; Lazinski, D.W.; Calderwood, S.B.; Camilli, A. A bacteriophage encodes its own CRISPR/Cas adaptive response to evade host innate immunity. Nature 2013, 494, 489–491. [CrossRef] [PubMed]
14. Parasion, S.; Kwiatek, M.; Gryko, R.; Mizak, L.; Malm, A. Bacteriophages as an alternative strategy for fighting biofilm development. Pol. J. Microbiol. 2014, 63, 137–145. [PubMed]
15. Schmelcher, M.; Loessner, M.J. Application of bacteriophages for detection of foodborne pathogens. Bacteriophage 2014, 4, e28137. [CrossRef] [PubMed]
16. Nobrega, F.L.; Costa, A.R.; Kluskens, L.D.; Azeredo, J. Revisiting phage therapy: New applications for old resources. Trends Microbiol. 2015, 23, 185–191. [CrossRef] [PubMed]
17. Meaden, S.; Koskella, B. Exploring the risks of phage application in the environment. Front. Microbiol. 2013, 4, 358. [CrossRef] [PubMed]
18. Mohammed-Ali, M.N.; Jamalludeen, N.M. Isolation and characterization of bacteriophage against methicillin resistant Staphylococcus aureus. J. Med. Microb. Diagn. 2015, 5, 213.
19. Moradpour, Z.; Sepehrizadeh, Z.; Rahbarizadeh, F.; Ghasemian, A.; Yazdi, M.T.; Shahverdi, A.R. Genetically engineered phage harbouring the lethal catabolite gene activator protein gene with an inducer-independent promoter for biocontrol of Escherichia coli. FEMS Microbiol. Lett. 2009, 296, 67–71. [CrossRef] [PubMed]
20. Ormala, A.M.; Jalasvuori, M. Phage therapy: Should bacterial resistance to phages be a concern, even in the long run? Bacteriophage 2013, 3, e24219. [CrossRef] [PubMed]
21. Drulis-Kawa, Z.; Majkowska-Skrobek, G.; Maciejewska, B.; Delattre, A.S.; Lavigne, R. Learning from bacteriophages—Advantages and limitations of phage and phage-encoded protein applications. Curr. Protein Pept. Sci. 2012, 13, 699–722. [CrossRef] [PubMed]
22. Paul, V.D.; Sundarrajan, S.; Rajagopalan, S.S.; Hariharan, S.; Kempashanaiah, N.; Padmanabhan, S.; Sriram, B.; Ramachandran, J. Lysis-deficient phages as novel therapeutic agents for controlling bacterial infection. BMC Microbiol. 2011, 11, 195. [CrossRef] [PubMed]
23. Susianto, G.; Farid, M.M.; Dhany, N.R.; Addy, H.S. Host range for bacteriophages that infect bacterial blight pathogen on soybean. Procedia Environ. Sci. 2014, 20, 760–766. [CrossRef]
24. Addy, H.S.; Azizi, N.F.; Mihardjo, P.A. Detection of bacterial wilt pathogen and isolation of its bacteriophage from banana in lumajang area, indonesia. Int. J. Agron. 2016, 2016, 5164846. [CrossRef]
25. Rombouts, S.; Volckaert, A.; Venneman, S.; Declercq, B.; Vandenheuvel, D.; Allonsius, C.N.; Van Malderghem, C.; Jang, H.B.; Briers, Y.; Noben, J.P.; et al. Characterization of novel bacteriophages for biocontrol of bacterial blight in leek caused by Pseudomonas syringae pv. Porri. Front. Microbiol. 2016, 7, 279. [CrossRef] [PubMed]
26. Lee, C.N.; Lin, J.W.; Chow, T.Y.; Tseng, Y.H.; Weng, S.F. A novel lysozyme from xanthomonas oryzae phage varphixo411 active against xanthomonas and stenotrophomonas. Protein Expr. Purif. 2006, 50, 229–237. [CrossRef] [PubMed]
27. Wittmann, J.; Brancato, C.; Berendzen, K.W.; Dreiseikelmann, B. Development of a tomato plant resistant to Clavibacter michiganensis using the endolysin gene of bacteriophage CMP1 as a transgene. Plant Pathol. 2016, 65, 496–502. [CrossRef]
28. Rahmani, R.; Zarrini, G.; Sheikhzadeh, F.; Aghamohammadzadeh, N. Effective phages as green antimicrobial agents against antibiotic-resistant hospital Escherichia coli. Jundishapur J. Microbiol. 2015, 8, e17744. [CrossRef] [PubMed]
29. Chhibber, S.; Kaur, T.; Sandeep, K. Co-therapy using lytic bacteriophage and linezolid: Effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections. PLoS ONE 2013, 8, e56022. [CrossRef] [PubMed]
30. Wall, S.K.; Zhang, J.Y.; Rostagno, M.H.; Ebner, P.D. Phage therapy to reduce preprocessing Salmonella infections in market-weight swine. Appl. Environ. Microbiol. 2010, 76, 48–53. [CrossRef] [PubMed]
31. Richards, G.P. Bacteriophage remediation of bacterial pathogens in aquaculture: A review of the technology. Bacteriophage 2014, 4, e975540. [CrossRef] [PubMed]
32. Wang, Y.; Barton, M.; Elliott, L.; Li, X.; Abraham, S.; O'Dea, M.; Munro, J. Bacteriophage therapy for the control of Vibrio harveyi in greenlip abalone (Haliotis laevigata). Aquaculture 2017, 473, 251–258. [CrossRef]
33. Prasad, Y.; Arpana D; Kumar, D.; Sharma, A.K. Lytic bacteriophages specific to flavobacterium columnare rescue catfish, Clarias batrachus (linn.) from columnaris disease. J. Environ. Biol. 2011, 32, 161–168. [PubMed]
34. Atad, I.; Zvuloni, A.; Loya, Y.; Rosenberg, E. Phage therapy of the white plague-like disease of Favia favus in the red sea. Coral Reefs 2012, 31, 665–670. [CrossRef]
35. Takemura-Uchiyama, I.; Uchiyama, J.; Osanai, M.; Morimoto, N.; Asagiri, T.; Ujihara, T.; Daibata, M.; Sugiura, T.; Matsuzaki, S. Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice. Microbes Infect. 2014, 16, 512–517. [CrossRef] [PubMed]
36. Biswas, B.; Adhya, S.; Washart, P.; Paul, B.; Trostel, A.N.; Powell, B.; Carlton, R.; Merril, C.R. Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 2002, 70, 204–210. [CrossRef] [PubMed]
37. Hatfull, G.F. Mycobacteriophages: Windows into tuberculosis. PLoS Pathog. 2014, 10, e1003953. [CrossRef] [PubMed]
38. Bruttin, A.; Brüssow, H. Human volunteers receiving Escherichia coli phage T4 orally: A safety test of phage therapy. Antimicrob. Agents Chemother. 2005, 49, 2874–2878. [CrossRef] [PubMed]
39. Sarker, S.A.; Sultana, S.; Reuteler, G.; Moine, D.; Descombes, P.; Charton, F.; Bourdin, G.; McCallin, S.; Ngom-Bru, C.; Neville, T.; et al. Oral phage therapy of acute bacterial diarrhea with two coliphage preparations: A randomized trial in children from Bangladesh. EbioMedicine 2016, 4, 124–137. [CrossRef] [PubMed]
40. Servick, K. Beleaguered phage therapy trial presses on. Science 2016, 352, 1506. [CrossRef] [PubMed]